Introduction
Bleomycin hydrolase (BH) is a cysteine protease with unusual structural and biological features. The enzyme was discovered due to its ability to deactivate the glycopeptide antibiotic, bleomycin, which is used as a therapeutic agent in the treatment of a number of forms of cancer. This endogenous enzyme is overexpressed in some tumor cells and is thought to be a major cause of tumor cell resistance to bleomycin therapy [1] . Studies on BH knockout mice indicated that BH is important for neonatal survival [2] . In addition, these studies showed that in mammalian cells BH is the only enzyme with bleomycin deamidation activity. Interest in the clinical relevance of BH was heightened by a recent report of the genetic linkage of an allelic variant to Alzheimer's disease (AD) [3] .
BH is widely distributed throughout nature with homologs found in bacteria [4] [5] [6] [7] [8] [9] , yeast [10] [11] [12] [13] , amphibians [14] , birds [15] and mammals [16] [17] [18] . Its expression in animals does not appear to be tissue-specific. There is high sequence identity between the different forms of BH with, for example, the yeast form exhibiting 35% and 41% identity with the bacterial and human forms, respectively.
The evolutionary conservation and wide distribution of the enzyme suggests that it has a conserved cellular function. This function has yet to be elucidated, however. The enzyme has been named bleomycin hydrolase as isolated from mammalian cells for its capacity to detoxify bleomycin, and Gal6 from yeast for its ability to regulate the galactose inducible genes.
The crystal structure of the yeast BH, Gal6, has been solved and reveals a hexameric ring barrel structure with the active sites embedded in a central cavity [19] . This cavity is 22 Å wide at the openings at either end, and widens to 45 Å in the interior of the protein. The only access to the active sites is through the cavity, and thus a protein substrate would need to be at least partially unfolded or degraded in order to reach them. BH has little substrate specificity so it is reasonable to assume that this sequestration of the active sites is necessary to prevent indiscriminate proteolysis. This places BH in the class of 'self-compartmentalizing proteases' with, for example, the proteosome and the tricorn protease [20, 21] . The C terminus of Gal6 lies in the active site, in much the same position as that taken by inhibitors in complex with the protease papain. Recent work on Gal6 has shown that the enzyme acts as a carboxypeptidase on its own C terminus to convert itself to an aminopeptidase and peptide ligase [22] . The C terminus anchors the substrate into the active site and confers 'positional' specificity. This model also serves to explain the singular ability of Gal6 to inactivate bleomycin. In addition to the protease activity, at least some members of the BH family have a nucleic acid binding activity. The yeast form of BH strongly binds RNA, single-stranded DNA and nicked double-stranded DNA [13, 23] .
In view of the clinical relevance of this protein, we have determined the crystal structures of wild-type human BH (hBH) and of a mutant form of the enzyme. We have also examined the nucleic acid binding activity and cellular localization of hBH in comparison to the yeast form, in an attempt to gain further insight into the conserved cellular functions of the enzyme.
Results and discussion
The overall structure
The structure of hBH is presented in Figure 1 . Both the wild-type and mutant structures were solved by molecular replacement, using Gal6 as a search model, and refined to 2.6 Å and 1.85 Å resolution, respectively. Crystallographic statistics are reported in Table 1 . The structure of hBH was expected to be very similar to that of the yeast form due to the sequence similarity. Superpositions between the monomers and the hexamers of the yeast and human proteins are shown in Figure 2a . The root mean square (rms) deviation of Cα atoms is 1.23 Å between two monomers and 1.43 Å between two hexamers. It has been suggested [24] that the low sequence similarity between the N-terminal domains of the yeast and human enzymes implies structural divergence at the N terminus, which in turn could result in hBH forming a tetramer rather than the hexamer formed by Gal6. We find, however, that the structures are very similar even in this region, with the exception of the first six residues which point in different directions.
The C terminus
The C terminus of Gal6 is flexible, allowing it to rotate and move in the active-site cleft. This flexibility defines the enzymatic activity of the protein by controlling the 620 Structure 1999, Vol 7 No 6
Figure 1
The structure of hBH. The six subunits are shown in different colors. (a) Top view of the hexamer down the threefold axis. Dimer interactions occur between the top and bottom subunits (between the red and blue, yellow and purple, and orange and green subunits). (b) Side view, with the hexamer rotated 90° about the y axis. The dimer interactions are clearly visible, with the socalled 'hook' domains of the yellow and blue subunits hooking over the purple and red subunits, respectively. (The figure was prepared with the programs Bobscript [41] , Molscript [42] and Raster3D [43] .) Table 1 Crystallographic data and refinement statistics.
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Wild type Cys73→Ser/∆Glu455 
Figure 2
Comparison of the human and yeast BH enzymes. (a) Superposition of hBH on yeast Gal6. The left and right panels show superimposed hexamers and monomers, respectively. The structures are shown as Cα traces, with the human protein shown in red and the yeast protein in green. The structures were superimposed using a least-squares alignment based on the conserved sequences around the active-site residues. (b) Alignment of the human (hBH) and yeast BH (Gal6) amino acid sequences. Identical residues are highlighted in green, with asterisks marking the active-site residues. Secondary structure motifs are colored according to domain: the hook domain is in red; the core papain-like domain is in green; the helical domain is in blue; and the C-terminal region is in pink.
Residues are numbered according to the human sequence. (c) GRASP [44] representations of the electrostatic surface potential for hBH and Gal6. The color scheme depicts potentials < -10 k B T in red and > 10 k B T in blue, where k B is the Boltzmann constant and T is the absolute temperature. For this calculation, the dielectric constants were 80 for the solvent and 2 for the protein; the ionic strength was 0. The top panels show hBH and the lower panels show Gal6. The left panels show a top view down the threefold axis; the panels on the right show a slice through the protein approximately along the threefold axis, highlighting the difference in charge between interiors of the human and yeast proteins.
position of the C terminus in the active site [22] . It is this control that determines the diverse potential activities of Gal6. In Gal6 the C-terminal amino acid is encoded as lysine. This residue is removed in an autocatalytic reaction, truncating the protein at the end of the conserved eight-residue C-terminal sequence that is found in all BH enzymes. The corresponding residue in the human protein is glutamic acid. In spite of the difference in charge, we find that the glutamic acid residue in hBH is also removed, implying that the carboxypeptidase activity of BH is charge insensitive.
In order to determine if hBH displays the same flexibility of the C terminus as the yeast enzyme, we solved the structure of a mutant in which the active-site cysteine was converted to serine (Cys73→Ser/∆Glu455). As this alteration abolishes the peptidase activity of the protein (see Materials and method section), the terminal glutamic acid (Glu455) was genetically removed to produce an authentic C terminus. Apart from the C-terminal arm, the structures of the wild-type and the mutant proteins are virtually identical, with an rms deviation for Cα atoms of 0.25 Å, even though they belong to different crystal forms and thus undergo different packing interactions. In a similar fashion to the Cys73→Ala/∆Lys454 mutant of Gal6 [22] , Ala454 of the hBH mutant moves further towards the active site to occupy the P1 position (for nomenclature see [25, 26] ), which is open in the wild-type protein ( Figure 3 ). In hBH, Gly451, which is the equivalent of Gly450 in yeast, also allows the chain to rotate and extend at that point by a screw-like movement to allow this repositioning of the C terminus. However, in this case it is a serine rather than an alanine that replaces the nucleophilic cysteine, Cys73. In order for this movement to take place, Met370 moves out of the way of the repositioned Leu453.
In addition, the hydroxyl group of Ser73, which as cysteine in the wild-type protein is somewhat mobile and moves between positions where it either interacts with the carbonyl of residue 71 or with the amide of residue 373, is hydrogen bonded to the amide of residue 373. One of the C-terminal carboxylate oxygens interacts both with the amide of Ser73 and with Gln67 in the oxyanion hole, and the other interacts with the amide group of Trp74. It appears that the choreography of the C terminus has been conserved between the yeast and human forms of BH.
Human versus yeast BH
The most striking difference between the yeast and human forms of BH is the charge distribution. Although the overall charge of the yeast protein is neutral, the central channel is lined with 60 lysine residues and as a result has a strong positive electrostatic potential (see Figure 2c ; bottom). This charge distribution suggested that the central channel was the site of nucleic acid binding. The mutation to alanine of three lysine residues from each monomer that are found at the entrance to the channel abolished the nucleic acid binding activity [23] . Although this mutation did not affect Gal6 activity in vitro, yeast cells expressing only the non-DNA-binding protein had much reduced resistance to bleomycin, indicating that the nucleic acid binding activity does have a role in bleomycin detoxification in yeast in vivo [27] . In hBH, two of the corresponding lysine residues of the yeast protein are present, whereas the third is an asparagine. However, hBH has a slightly negative electrostatic potential in the channel (see Figure 2c ; top). The calculated pI for hBH is 6.0. Whether or not mammalian BH binds DNA or RNA is controversial: it has been reported that the rat form from cell extracts does bind DNA [18] , whereas the human form produced in Escherichia coli does not [16, 24] . Interestingly, the bacterial BH, PepC, which has a calculated pI of 4.8 for the hexamer, does bind single-stranded DNA (HE Xu and SAJ, unpublished data). It should be noted that the yeast BH, Gal6, is the only member of the family known to date to have a basic pI.
DNA binding and cellular localization
A gel shift assay was employed to determine if hBH binds nucleic acid. As evident in Figure 4a , the yeast form of BH binds a single-stranded oligonucleotide avidly, but there is no evidence of binding in the human cell extracts. Enzyme assays ( Figure 4a inhibitory. We conclude that hBH does not have the nucleic acid binding properties of Gal6. As pointed out above, hBH only has two of the three lysine residues at the entrance of the channel which are required for nucleic acid binding by Gal6. This is not sufficient to explain the difference in binding, however, as the bacterial and rat forms of BH, both of which have nucleic acid binding activity, also have only one or two of these lysines, respectively. Apparently, the nucleic acid binding activity also involves other sequences. Immunolocalization studies indicate that the yeast form of BH is largely localized to the cytoplasm and excluded from the nucleus [27] ; hBH also appears to be largely cytoplasmic with relative exclusion of localization in the nucleus (Figure 4b ). This suggests that the human and yeast proteins not only have the same structure, but may also perform the same cellular functions.
hBH and Alzheimer's disease
The β-amyloid peptide (Aβ) associated with Alzheimer's disease (AD) is a peptide of 40-42 amino acids derived from the amyloid precursor protein (APP) and accumulates in the amyloid plaques of both 'sporadic' and familial cases of AD [28] . Aβ is thought to be produced by proteolytic processing by a β-secretase at its N terminus and a γ-secretase at its C terminus, both of which have yet to be identified. A cysteine protease purified from AD brain by virtue of its ability to cleave a synthetic peptide encompassing the β-secretase cleavage site was found to associate with APP [29] and later identified as hBH (C Abraham, personal communication). Recently, it was reported that there is a genetic linkage of an allelic variant of hBH to the non-familial form of AD [3] , although a subsequent study on a different population failed to detect the same association [30] . This may or may not relate to APP processing directly. The disease-linked form of hBH has a valine at position 443, as opposed to an isoleucine in the other isoform. Interestingly, Gal6, also has valine at this position. In addition, this is one region that shows divergence between the yeast and human proteins, with the loop preceding residue 443 being quite different in structure. This loop is not involved in any crystal contacts in any of the three crystal forms. It appears that the differences in conformation in this region are largely due to a three-residue insertion five residues N-terminal to this isoleucine. In fact, for the residues following Ile443, the polypeptide chains track each other again very closely. Residue 443 sits at the edge of a charged cleft on the surface of the molecule. Five residues C-terminal to this isoleucine is Trp447, which is part of the conserved C-terminal arm. Trp447 is involved in a four-residue stacking interaction with Arg131 and their counterparts in the dimer-related subunit ( Figure 5 ). The chain is then inserted into the barrel of the protein and descends into the active-site cleft. As the sidechain of this isoleucine residue does not appear to be involved in any intramolecular or any monomer-monomer interactions, or even in any crystal contacts, it is unlikely that removing a methyl group, as would be the case for a valine substitution, would affect the protein conformation per se. We have previously suggested that the activity of Gal6 could be controlled by interaction with a protein that altered the position of the C-terminal arm [19] , and have shown that the positioning of the C terminus has profound effects on the enzymatic activity of Gal6 [22] . The region around residue 443 is a likely candidate for interaction with such a regulatory protein. As the I/V polymorphism associated with AD is not expected to substantially change the structure of hBH, we suggest that if it does have a biological effect this probably arises from modifications in the interaction of hBH with another protein.
Biological implications
The clinical use of bleomycin is limited due to drug resistance [1, 31] and dose-dependent production of pulmonary fibrosis [32] . Resistance to antineoplastic drugs, whether intrinsic or acquired, is a major problem in the treatment of human cancers. Bleomycin hydrolase (BH) was shown to be a cysteine protease that detoxifies bleomycin by hydrolysis of the amide bond in the β-aminoalanine moiety, producing inactive metabolites [33] . This appears to limit the effectiveness of the drug, as cancer cells with increased expression of BH are resistant to drug treatment. In addition, tissues with naturally low levels of BH, such as skin and lung, are particularly sensitive to bleomycin [34] and it was recently shown that in mammalian cells BH is the only enzyme with bleomycin deamidation activity [2] .
As mammals rarely encounter bleomycin, bleomycin hydrolysis is probably not the normal function of the enzyme. Studies with BH knockout mice have shown that BH is important for neonatal survival [2] . BH is widely distributed throughout nature with homologs found in bacteria, yeast, birds and mammals; the different forms of BH exhibit high sequence identity. The yeast form of BH, Gal6, negatively regulates the galactose metabolism system and also binds single-stranded DNA and RNA with high affinity [27] . Nucleic acid binding activity was also reported for other members of the family [18] . The structure of Gal6 [19] represents one of the first examples of an emerging class of self-compartmentalizing proteases, along with the 20S proteasome [35] . The C terminus of Gal6 lies in the active site and controls the activities of the enzyme including its unique ability to inactivate bleomycin [22] .
In solving the structure of human BH, we found a very similar overall structure to that of the yeast form, as expected from the sequence identity. However, the central channel, which has a very prominent positive charge in the yeast enzyme, is slightly negatively charged in the human protein. Indeed, we have shown that human BH does not have the DNA-binding activity of the yeast protein. This may reflect a somewhat different or perhaps altered role in their respective biological functions.
Recently, the clinical relevance of human BH has been augmented by its possible association with Alzheimer's disease. The structure suggests that the location of a putative disease-linked variation could affect interactions with another protein, which in turn may modulate the peptidase activity of human BH by repositioning the C terminus. If indeed there is an involvement of human BH in some Alzheimer's disease pathology, the structural and functional similarities and differences between the yeast and human forms may prove useful in delineating the disease mechanism. In addition, the structure of human BH may now serve as a basis for the rational design of inhibitors of BH activity to augment the effectiveness of bleomycin in cancer treatment.
Materials and methods

Protein expression and purification
The gene encoding hBH was kindly provided by Carlos López-Otín at the Universidad de Oviedo [17] . The gene fragment was isolated by the polymerase chain reaction (PCR) using two oligonucleotides (the 5′ primer is 5′-GGCAGCGTGGGCGCCATGAGCAGCTC-3′ and the 3′ primer is 5′-CGCGGATCCAGTATCACTCAGCCAAAGC-3′) and digested using Nar I and Bam HI. The resulting fragment was cloned into the bacterial expression vector pKH260. This vector is the same as pKM260, which has been previously described [22] , with the exception that a 1kb Bgl II-Bsm I fragment in the tet R gene was deleted to eliminate four Nar I sites. This vector produces an expressed protein construct in which a six-histidine tag is attached to the N terminus of the protein via a tobacco etch virus protease (TEV) cleavage site. The Cys73→Ser/∆Glu455 double mutant was made using a procedure similar to that previously described. Briefly, the active-site cysteine was changed to serine by sitedirected mutagenesis using two complementary oligonucleotides (5′-GAGCTCAGGGCGATCGTGGATCTTTTCTTGTC-3′ and 5′-GACAAGAAAAGATCCACGATCGCCCTGAGCTC-3′). Then Glu455 was deleted by PCR using the 5′ primer and the deletion oligonucleotides (5′-CGGGATCCGTATCAAGCCAAAGCTCCCATGGG-3′). The gene encoding the double mutant was cloned into pKH260 and the full length of the gene has been sequenced to confirm the mutation. The vectors were transformed into E. coli strain BL21 with pLysS for protein expression. The cells were grown in Luria broth (LB) to mid-log phase (OD 600~0 .45) then hBH production was induced with 200 µM isopropyl-β-D-thiogalactosyl pyranoside (IPTG). The cells were grown for a further 5 h and then harvested, resuspended in 50 mM Na phosphate (pH 8.5), 300 mM NaCl, 7 mM β-mercaptoethanol and frozen overnight at -80°C. 300 µl Triton-X-100 and 15 µl β-mercaptoethanol were added per liter of culture and the cells were thawed at room temperature, sonicated and centrifuged. hBH was purified from the cell-free extract with a combination of nickel affinity, ion exchange and gel-filtration chromatography. The gel-filtration step also served to exchange the buffer to that used during crystallization. The protein was concentrated using a Millipore ultrafree centrifugal filter to 30-50 mg/ml and stored at 4°C. The histidine-tag was not removed.
Protease assays
To assay protease activity, hydrolysis of the fluorogenic substrates citrulline-aminomethyl coumarylamide (H . Cit-AMC; Bachem), and arginine-aminomethyl coumarylamide (H . Arg-AMC; Bachem) were measured using a modified version of the Gal6p protease assay as described by Xu and Johnston [13] . In these assays, 100 ng hBH or the Cys73→Ser/∆Glu455 mutant protein were incubated in protease assay buffer (200 mM KH 
Crystallization and data collection
Human BH crystallized in a range of conditions from 16-20% PEG 10 K and pH 7-8.5. Crystallization was carried out at 17°C by the hanging-drop vapor diffusion method. Drops were prepared by mixing 1 µl of well solution with 1 µl of protein solution (12 mg/ml in 25 mM Tris, pH 8.0, 5% glycerol, 140 mM KCl and 1 mM DTT). The protein initially formed a precipitate that dissolved over a number of days and from which the crystals grew. The mutant protein formed crystals in space groups C222 1 and R32; data have been collected for the wildtype protein in space group C222 1 .
Data were collected at the National Synchrotron Light Source (NSLS) on beamlines X26C and X25 on MAR imaging plates (300 mm at X26C and a 345 mm at X25) using cryocrystallography techniques. Crystals were soaked in a cryoprotectant solution (well solution plus 30% ethylene glycol), mounted on loops and frozen directly into the nitrogen stream. The reflection intensities were integrated and scaled with the HKL [36] suite of programs. Each data set was collected from a single crystal. In the case of the mutant protein, two data sets were collected from the same crystal at resolution ranges of 30-3.0 Å and 3.5-1.85 Å to avoid saturation of the high intensity low-angle reflections. Data for the wild-type protein extended to 2.59 Å.
Solution and refinement
A polyalanine model was generated based on the structure of Gal6 with appropriate deletions and insertions made where the sequences diverged. A trimer of this model, based on half the hexameric structure of the yeast protein was used to solve the wild-type C222 1 crystal by molecular replacement using the program AMoRe [37] . This gave a solution with an R factor of 0.478 and a correlation coefficient of 0.347. Crystallographic symmetry operations generated the biologically relevant hexameric structure confirming the correctness of the solution. The R32 structure was solved with a model which had been partially rebuilt in the wild-type data set. In this case the search model used consisted of two independent monomers. The 32 crystallographic symmetry generates a hexamer from each of the two monomers in the asymmetric unit.
Model-building was carried out using the program O [38] and refinement using CNS [39] with a maximum-likelihood target function [40] and a flat bulk-solvent correction. No σ cut-off was applied to the data. Noncrystallographic symmetry (NCS) constraints were used for the wild-type data which refined to an R cryst of 0.238 and R free of 0.261. In the final stages of refinement of the mutant data set, NCS restraints were released and after the inclusion of alternate sidechain conformations for 15 residues (seven in molecule A and eight in molecule B) and 563 water molecules, the R cryst and R free reached 0.182 and 0.210, respectively. The electron-density maps are essentially complete, except for the extreme N terminus containing the histidine-tag and linker for which no density can be seen, and the loop from residues 383-387, for which the density is difficult to interpret. A F o -F c omit map for the 440's loop region is shown in Figure 6 . The published sequence has a tyrosine at position 280, which we found to be a histidine. This could either be a variant, from the source or through propagation, or there could have been a sequencing error. The DNA sequence varies only by one base. This residue is on the surface of the protein and therefore this difference should not have a significant effect on the structure.
Gel mobility shift assays
Nucleic acid binding properties of BH in wild-type yeast and HeLa cell extracts were examined by gel mobility shift assays, as described previously [13] , with a modification in the sequence of the single-stranded oligonucleotide used (5′-AGCTTAGCGGAAATTTGTGGTCGCA-3′). In addition, 150 ng recombinant Gal6 was added to the HeLa extracts in a mixing experiment. The presence of hBH in whole cell extracts was verified by western blot analysis using purified anti-hBH IgG generated in rabbits. In order to compare the nucleic acid binding properties in human and yeast whole cell extracts, equivalent amounts of hBH and Gal6 protease activity were included in the binding reaction. Specific hBH or Gal6 activity was recorded as the amount of protease activity in each extract that was capable of being inhibited by the cysteine protease specific inhibitor L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane (E64; Sigma). Relative specific activity in extracts was defined as units of E64-inhibitable protease activity × min -1 × mg protein -1 .
Antibody purification and immunolocalization
Polyclonal hBH antibody was raised in rabbits immunized with recombinant hBH. IgG was purified from crude serum using a protein A column (Pierce). Affinity purification of anti-hBH antibody from the IgG was performed using highly purified hBH protein. HeLa cells were seeded at a density of 1-3 × 10 4 per chamber in a glass chamber slide (Nunc). For immunofluorescence staining, cells were washed twice in phosphate buffered saline (PBS) and fixed in a 4% para-formaldehyde PBS solution. Cells were washed twice and fixation was stopped by the addition of 100 mM ammonium chloride PBS. Cells were then permeabilized by incubation in 0.1% Triton X100-PBS, washed twice and blocked in 1% bovine serum albumin (BSA) in PBS. Primary antibody incubations were performed overnight at 4°C and were followed by three washes in 0.08% BSA/0.01% saponin in PBS (wash buffer). Secondary antibody incubations were carried out with fluorescein-conjugated goat antirabbit IgG (Pierce) for 2 h at room temperature. Slide chambers were then washed three times in wash buffer, twice in PBS and six times in filter-sterilized distilled water. Slides were air-dried and covered with vectashield (Vector Laboratories). Images were captured using a Leitz Laborlux-S epifluorescent photomicroscope possessing an Optronics V1470 CCD array camera as well as Signal Analytics IP lab spectrum capture and analysis software.
Accession numbers
The atomic coordinates of the wild-type and mutant hBH structures have been deposited in the Protein Data Bank with accession numbers 1cb5 and 2cb5, respectively.
Figure 6
Stereoview F o -F c omit map for residues 441-447 of the Cys73→Ser/∆Glu455 mutant of hBH, with the final structure superimposed. The map is contoured at 3σ and shows the quality of the structure in the region of the AD-linked allelic variation.
